US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% SNDK $1,719.99 ▲+0.00% NVDA $233.95 ▲+0.00% SPCX $158.96 ▲+0.00% AMD $633.91 ▲+0.00% WDC $415.29 ▲+0.00% TSLA $370.59 ▲+0.00%
FinancialContent

Moderna, Inc. - Common Stock (NQ:MRNA)

190.01 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
BioNTech Threw in the Towel on Its Colorectal Cancer Vaccine Trial. Should Investors Be Worried? ↗
BioNTech's recent pipeline setback is a real cause of concern. But investors shouldn't panic. 
Via The Motley Fool
What's going on in today's session: S&P500 movers ↗
Via Chartmill
News headline image
Why Are Moderna (MRNA) Shares Soaring Today
What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 7.1% in the afternoon session after the company presented at the Morgan Stanley G... 
Via StockStory
Topics Artificial Intelligence
Which S&P500 stocks are moving on Thursday? ↗
Via Chartmill
Thursday's pre-market session: top gainers and losers in the S&P500 index ↗
Via Chartmill
News headline image
A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
EQNX::TICKER_START (NYSE:NNVC),(NASDAQ:GILD),(NASDAQ:MRNA),(NYSE:PFE),(NASDAQ:BNTX) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
A Growing Global Threat From Emerging Viruses Is Fueling Urgent Demand For New Treatments And Creating A Potentially Massive Market For Innovative Antiviral Developers 
From MarketNewsUpdates.com
Via GlobeNewswire
News headline image
Unpopular Stocks Walking a Fine Line
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cord... 
Via StockStory
News headline image
Moderna's COVID Vaccine Was a Historic Success. Could Its Cancer Vaccine Be Even Bigger? ↗
The biotech is entering a new era. 
Via The Motley Fool
News headline image
Moderna’s Cancer Vaccine Win Fuels Broad Push Across Tumor Types ↗
Moderna (NASDAQ:MRNA) President Stephen Hoge said the company’s recently announced positive Phase III results for its investigational personalized cancer vaccine, intismeran, in adjuvant melanoma... 
Via MarketBeat
News headline image
Blue-Chip Stocks Are Looking Anything But Boring With Dividends and Big 2026 Gains ↗
Coca-Cola, Chevron, and Merck have outperformed the S&P 500 in 2026, each pairing strong share-price gains with growing dividends backed by solid fundamentals. 
Via MarketBeat
Topics Artificial Intelligence Intellectual Property Stocks
News headline image
3 Cash-Burning Stocks We Approach with Caution
Rapid spending isn’t always a sign of progress. Some cash-burning businesses fail to convert investments into meaningful competitive advantages, leaving them... 
Via StockStory
Top S&P500 movers in Friday's session ↗
Via Chartmill
Stay informed with the top movers within the S&P500 index on Friday. ↗
Via Chartmill
News headline image
Moderna, 10x Genomics, Oscar Health, and Novavax Shares Are Soaring, What You Need To Know
What Happened? A number of stocks jumped in the morning session after Morningstar reported that challenging macroeconomic conditions across broader equity ma... 
Via StockStory
News headline image
Amgen vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026? ↗
Amgen trades at a fraction of Moderna's valuation, but one company is burning cash while the other generates billions, a critical divide for income-focused investors. 
Via The Motley Fool
News headline image
Behind the Most Exciting Stock Pop in Years ↗
Moderna's stock is up over 100%. 
Via The Motley Fool
Topics Artificial Intelligence Initial Public Offering World Trade
News headline image
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It ↗
Moderna, Pharvaris and AbbVie span short, mid and long-term healthcare setups, from melanoma data to a Phase 3 catalyst and 13 straight years of dividend hikes. 
Via MarketBeat
Topics Artificial Intelligence Bonds
News headline image
If You'd Invested in Moderna (MRNA) Stock 5 Years Ago, Here's How Much You'd Have Today (Hint: You'd Be Disappointed -- But Not If You Bought It 1 Year Ago.) ↗
Moderna shares have soared, sunk, and soared again. You might want to consider them. 
Via The Motley Fool
News headline image
Wall Street Has Cooled on Moderna After Its Stock Jumped Over 5X. But Does the mRNA Leader Have More Room to Run? ↗
The vaccine maker is making an increasingly robust case that it isn't just a pandemic stock. 
Via The Motley Fool
Stay updated with the S&P500 stocks that are on the move in today's pre-market session. ↗
Via Chartmill
News headline image
3 Inflated Stocks with Open Questions
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, u... 
Via StockStory
News headline image
BioNTech vs. Moderna: Which Is the Better Cancer Vaccine Stock to Buy Now? ↗
Both have attracted considerable attention from Wall Street recently. 
Via The Motley Fool
News headline image
Why Moderna (MRNA) Stock Is Down Today
What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 2.9% in the afternoon session after Rothschild & Co Redburn analyst Simon Baker dow... 
Via StockStory
Thursday's session: top gainers and losers in the S&P500 index ↗
Via Chartmill
These S&P500 stocks are moving in today's session ↗
Via Chartmill
News headline image
3 Stocks Whose Competitive Walls Tower Over Nvidia's ↗
A solid moat favors revenue growth, and that's good news for investors. 
Via The Motley Fool
Topics Artificial Intelligence
These S&P500 stocks are moving in today's pre-market session ↗
Via Chartmill
News headline image
Is BioNTech Stock a No-Brainer Buy on the Dip? ↗
The company is coming back into the spotlight thanks to recent developments. 
Via The Motley Fool
Stay informed with the top movers within the S&P500 index on Wednesday. ↗
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >